---
title: The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia
nct_id: NCT06205771
overall_status: ENROLLING_BY_INVITATION
phase: NA
sponsor: Hao Feng
study_type: INTERVENTIONAL
primary_condition: Preeclampsia
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06205771.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06205771"
ct_last_update_post_date: 2024-04-10
last_seen_at: "2026-05-12T06:34:48.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

**Official Title:** The Role and Mechanism of GPER Hippo Pathway in Regulating Uterine Arterial Smooth Muscle CBS/H2S in the Pathogenesis of Preeclampsia

**NCT ID:** [NCT06205771](https://clinicaltrials.gov/study/NCT06205771)

## Key Facts

- **Status:** ENROLLING_BY_INVITATION
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 54
- **Lead Sponsor:** Hao Feng
- **Conditions:** Preeclampsia
- **Start Date:** 2024-04-10
- **Completion Date:** 2029-12
- **CT.gov Last Update:** 2024-04-10

## Brief Summary

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

* The pathological significance of GPER in uterine artery dilation in preeclampsia
* The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

## Detailed Description

1. Measure the content of H2S in uterine arterial smooth muscle and circulation of normal pregnancy and PE pregnant women, and analyze the relationship between the content of H2S in uterine arterial smooth muscle and circulation of PE pregnant women and PE.
2. Knock down the GPER and overexpression of GPER in HTR-8 cells, and detect the expression of GPER, CBS, and Hippo pathway related proteins using Western blot and qRT-PCR to verify the efficiency of knockdown and overexpression. Use different concentrations of H2S donor (GYY4137) to interfere with HTR-8 cells after treatment, and use RT-PCR and Western blot to detect the mRNA and protein expression of downstream molecules YAP and TAZ in Hippo pathway in cells, respectively.

## Eligibility

- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman
2. Pregnant women undergoing lower segment cesarean section for delivery

Exclusion Criteria:

1. Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases;
2. Multiple pregnancy
3. Pregnant women undergoing vaginal delivery
4. Normal pregnant women who are\<37 weeks or\>40 weeks pregnant
```

## Arms

- **NP** (NO_INTERVENTION) — normal pregnancy and preeclampsia pregnancy
- **PE** (EXPERIMENTAL) — preeclampsia

## Interventions

- **H2S content** (OTHER) — H2S content

## Primary Outcomes

- **H2S content in uterine arterial smooth muscle circulation** _(time frame: 8:00 am)_ — H2S content in circulation

## Locations (1)

- The First Affiliated Hospital of Shandong First Medical University &Shandong Provincial Qianfoshan Hospital, Jinan, Please Select, China

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `locations.the first affiliated hospital of shandong first medical university &shandong provincial qianfoshan hospital|jinan|please select|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06205771.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06205771*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*